Does Rallies show 13F holders for CMPS?

Yes. Rallies tracks hedge fund and 13F ownership data for CMPS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CMPS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CMPS. It does not provide personalized investment advice.

CMPS (COMPASS Pathways Plc American Depository Shares) Stock Analysis - Hedge Fund Holdings

COMPASS Pathways Plc American Depository Shares (CMPS) is a publicly traded Healthcare sector company. As of May 21, 2026, CMPS trades at $10.87 with a market cap of $1.43B and a P/E ratio of -3.47. CMPS moved +8.04% today. Year to date, CMPS is +65.70%; over the trailing twelve months it is +135.28%. Its 52-week range spans $2.25 to $11.65. Analyst consensus is strong buy with an average price target of $23.50. Rallies surfaces CMPS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CMPS stock?

Hedge funds tracked by Rallies that own CMPS include Orbimed Advisors and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for COMPASS Pathways Plc American Depository Shares.

CMPS Key Metrics

Key financial metrics for CMPS
Metric	Value
Price	$10.87
Market Cap	$1.43B
P/E Ratio	-3.47
EPS	$-3.08
Dividend Yield	0.00%
52-Week High	$11.65
52-Week Low	$2.25
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-287.86M
Gross Margin	0.00%

Top Hedge Funds Holding CMPS

Orbimed Advisors holds 1.15M shares of CMPS, changed +0.00% as of Mar 31, 2026.
Centerbook Partners holds 409.24K shares of CMPS, changed -29.30% as of Mar 31, 2026.

Latest CMPS News

Compass Pathways Confirms Full Phase IIb Enrollment and Mid-2027 Cash Runway — May 14, 2026
Compass Pathways Shares Hit Two-Year High After Q1 Clinical Advances — May 13, 2026
Compass Pathways Gains 25% After FDA Rolling NDA Review and Priority Voucher — Apr 27, 2026
Cannabis Roundup: Jushi’s $160M Loan, Auxly’s 24% Growth, Canopy Leadership — Mar 29, 2026
Compass Pathways’ Psilocybin Phase 3 Shows 3.8-Point MADRS Benefit — Mar 9, 2026

Recent CMPS Insider Trades

ATAI Life Sciences N.V. sold 2.66M (~$16.09M) on Sep 26, 2024.
Malievskaia Ekaterina sold 8.90K (~$70.38K) on May 21, 2024.
Malievskaia Ekaterina sold 8.90K (~$70.38K) on May 21, 2024.

CMPS Analyst Consensus

12 analysts cover CMPS: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $23.50.

Common questions about CMPS

Who owns CMPS stock?: Hedge funds tracked by Rallies that own CMPS include Orbimed Advisors and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for COMPASS Pathways Plc American Depository Shares.
Does Rallies show 13F holders for CMPS?: Yes. Rallies tracks hedge fund and 13F ownership data for CMPS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CMPS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CMPS. It does not provide personalized investment advice.